Abstract Library

#3799 High-dose somatostatin analogues’ effects on glycolipid metabolism in patients with neuroendocrine tumors

Introduction: Somatostatin analogues (SSAs), octreotide and lanreotide, represent the cornerstone medical therapy of both sporadic and hereditary G1-G2 neuroendocrine tumors (NETs). Changes in glucose metabolism have been shown to occur during standard-dose SSA therapy, but no changes during high-dose therapy have been evaluated.

Conference:

Presenting Author:

Authors: Liccardi A, Minotta R, Cannavale G, Benevento E, Modica R,

Keywords: neuroendocrine tumor, somatostatin analogues, lipid, hyperglycaemia, high dose SSA, glycolipid metabolism,

#3782 Somatostatin analogues (SSA) in gastroenteropancreatic neuroendocrine tumors (GEP-NET) – Impact on glycemia and lipid profile in a monocentric series

Introduction: Somatostatin analogues (SSA) are often the first line therapy in neuroendocrine tumors (NET). The management of hyperglycaemia and dyslipidaemia are one of the most important challenges in healthcare. The impact of SSA on metabolic profile in GEP-NET is highly debated.

Conference:

Presenting Author: Cannavale G

Authors: Cannavale G, Benevento E, Minotta R, Liccardi A, Modica R,

Keywords: SSA, lipid profile, glycemia, GEP-NET, hyperglycaemia, Somatostatin analogues,